Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Pressure BioSciences, Inc.    PBIO

SummaryNewsCalendarCompanyFinancials 
News SummaryMost relevantAll newsSector newsTweets

Pressure Biosciences : Pressure BioSciences, Inc. to Present at the Rodman & Renshaw 8th Annual Healthcare Conference

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/02/2006 | 03:15pm CET

Pressure BioSciences, Inc. (NASDAQ: PBIO) today announced that it will present at the Rodman & Renshaw 8th Annual Healthcare Conference to be held at the New York Palace Hotel, New York, NY on November 6-8, 2006. Mr. Richard T. Schumacher, PBI President and CEO, will give a corporate overview at 9:55 am (EST) on Wednesday, November 8th. Investors will be able to hear the presentation starting on November 8th and for approximately 90 days thereafter at http://www.wsw.com/webcast/rrshq10/pbio/.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (PBI) is a publicly traded, early-stage company focused on the development of a novel, enabling technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. PBI currently holds 13 US and 5 foreign patents covering multiple applications of PCT in the life sciences field, including such areas as genomic and proteomic sample preparation, pathogen inactivation, the control of enzymes, immunodiagnostics, and protein purification.

Forward Looking Statements

Statements contained in this press release regarding the Company's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Quarterly Report on Form 10-QSB for the quarter ended June 30, 2006, in the Company's Annual Report on Form 10-KSB, as amended, for the year ended December 31, 2005, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

Visit us at our website http://www.pressurebiosciences.com


© Business Wire 2006
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PRESSURE BIOSCIENCES, INC.
11/21 PRESSURE BIOSCIENCES : Findings on Escherichia coli Reported by Investigators at..
11/14 PRESSURE BIOSCIENCES, INC. : Reports Third Quarter 2017 Financial Results and Pr..
11/13 PRESSURE BIOSCIENCES : Management's Discussion and Analysis of Financial Conditi..
11/13 PRESSURE BIOSCIENCES, INC. : to Discuss Third Quarter 2017 Financial Results and..
11/01 PRESSURE BIOSCIENCES : Initiates Aggressive Marketing and Sales Strategy Expecte..
10/30 HOW PRESSURE BIOSCIENCES IS REDEFINI : The Promise of New Drugs and Cures, High ..
10/26 NETWORKNEWSWIRE : Releases Exclusive Audio Interview with Pressure BioSciences I..
10/24 PRESSURE BIOSCIENCES INC : Pressure BioSciences, Inc. Discusses Market Opportuni..
10/23 PRESSURE BIOSCIENCES : PBIO) Engages NetworkNewsWire for Corporate Communication..
10/18 PRESSURE BIOSCIENCES : and Phasex Announce Strategic Collaboration Addressing Br..
More news
Managers
NameTitle
Richard T. Schumacher President, CEO, Secretary & Treasurer
Jeffrey N. Peterson Chairman
Joseph Luis Damasio Chief Financial Officer & VP-Finance
Edmund Y. Ting Senior Vice President-Engineering
Vito J. Mangiardi Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PRESSURE BIOSCIENCES, INC.4
MEDTRONIC PLC15.60%111 537
BAXTER INTERNATIONAL44.43%34 891
C R BARD INC49.19%24 432
ZIMMER BIOMET HOLDINGS INC9.56%22 894
ALIGN TECHNOLOGY164.62%20 396